AstraZeneca
Company Snapshot
Company Overview
AstraZeneca is a U.K.-based biopharmaceutical company. The company operates in three segments and is focused on our chosen therapy areas: Oncology, Biopharmaceuticals, and rare diseases. The Biopharmaceuticals segment comprises therapeutic areas, including cardiovascular, renal, and metabolism (CVRM), respiratory and immunology (R&I), and vaccines and immune therapies (V&I). The company’s products are sold in over 125 countries.
The company’s R&D focuses on bispecific, inhaled fragments, ADCs, and cell-depleting monoclonal antibodies in antibody therapeutics.
The major brands are Forxiga or Farxiga, Ebymect, Edistride, Xigduo, Bydureon, Lynparza, Bydureon, Xigduo, Edistride, and Ebymect.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Company's Business Segments
- Oncology : Cancer Care Africa, the Lung Ambition Alliance
- Rare Disease : Hypophosphatasia (HPP), Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN), Wilson disease, and Rare cancers.
- Other Medicines : Cardiovascular (CV), Renal & Metabolism, Respiratory & Immunology, and Vaccines & Immune Therapies.
Applications/End User Industries
- Oncology
- Cardiovascular
- Renal
- Metabolism
- Respiratory and Immunology (R&I)
- Vaccines and Immune Therapies (V&I)
- Rare Disease